Overview

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Collaborator:
Paragon Biomedical
Treatments:
Etanercept